Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.57 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.57 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | TDO2 | P48775 | 1/20 | 0.49 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20145059 | 0.85 | L3MBTL1 (0.49) | FPR2PROKR1MMP1POLBHTR2C | |
| SCHEMBL20069052 | 0.85 | HRH3 (0.56) | FPR2PROKR1MMP1HRH3 | |
| SCHEMBL30843204 | 0.85 | FPR2 (0.49) | FPR2PROKR1MMP1TDO2LIPE | |
| SCHEMBL21652006 | 0.84 | FPR2 (0.47) | FPR2PROKR1MMP1HTR2CHTR2B | |
| SCHEMBL13432215 | 0.83 | TDO2 (0.50) | FPR2PROKR1TDO2HRH3NAMPT | |
| SCHEMBL4051291 | 0.82 | FPR2 (0.47) | FPR2PROKR1MMP1LIPEHRH3 | |
| SCHEMBL941502 | 0.81 | FPR2 (0.64) | FPR2PROKR1MMP1TDO2 | |
| SCHEMBL20147962 | 0.81 | TDO2 (0.61) | TDO2MAPK7LIPEHRH3NAMPT | |
| SCHEMBL2816826 | 0.81 | TDO2 (0.49) | FPR2PROKR1TDO2HRH3NAMPT | |
| SCHEMBL3617804 | 0.81 | TDO2 (0.49) | FPR2PROKR1TDO2HRH3NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200383966-A9 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-12-10 | — | — | US | disclosed |
| US-20200030311-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2020-01-30 | — | — | US | disclosed |
| WO-2018071454-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-04-19 | — | — | WO | disclosed |
| US-9212147-B2 | Dihydroxy aromatic heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-15 | — | — | US | disclosed |
| US-9212147-B2 | Dihydroxy aromatic heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200383966-A9 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | FPR2 3689/4885PROKR1 438/4885MMP1 3562/4885 |
| US-20200030311-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | FPR2 3689/4885PROKR1 438/4885MMP1 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.